West Paces Advisors Inc. Has $1.68 Million Holdings in Eli Lilly and Company (NYSE:LLY)

West Paces Advisors Inc. decreased its stake in Eli Lilly and Company (NYSE:LLY) by 4.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 2,879 shares of the company’s stock after selling 128 shares during the quarter. West Paces Advisors Inc.’s holdings in Eli Lilly and Company were worth $1,678,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of LLY. Simon Quick Advisors LLC grew its stake in shares of Eli Lilly and Company by 10.5% in the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after acquiring an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC bought a new stake in Eli Lilly and Company during the fourth quarter worth $363,000. WASHINGTON TRUST Co boosted its holdings in shares of Eli Lilly and Company by 16.5% in the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock valued at $11,013,000 after purchasing an additional 2,671 shares in the last quarter. Liontrust Investment Partners LLP bought a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $8,326,000. Finally, Redhawk Wealth Advisors Inc. lifted its position in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Redhawk Wealth Advisors Inc. now owns 6,986 shares of the company’s stock worth $3,752,000 after buying an additional 65 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of Eli Lilly and Company stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the transaction, the insider now owns 99,488,598 shares in the company, valued at approximately $64,177,109,911.86. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.13% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have commented on the company. Morgan Stanley boosted their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. The Goldman Sachs Group increased their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Bank of America upped their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a report on Wednesday, February 21st. Finally, BMO Capital Markets lifted their price target on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Price Performance

NYSE:LLY traded down $4.03 during trading hours on Tuesday, hitting $746.74. 2,501,475 shares of the stock traded hands, compared to its average volume of 3,085,198. The company has a market cap of $709.52 billion, a price-to-earnings ratio of 128.34, a price-to-earnings-growth ratio of 1.65 and a beta of 0.34. Eli Lilly and Company has a 1 year low of $367.35 and a 1 year high of $800.78. The stock has a 50 day moving average price of $762.68 and a 200 day moving average price of $655.54. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the prior year, the business posted $2.09 earnings per share. The company’s quarterly revenue was up 28.1% compared to the same quarter last year. Sell-side analysts forecast that Eli Lilly and Company will post 12.46 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.